Treatment of Bacterial Vaginosis During Pregnancy

First Trimester Treatment Options

• The Centers for Disease Control and Prevention recommends Clindamycin vaginal cream 2% as the first-line treatment for bacterial vaginosis during the first trimester, administered as one full applicator intravaginally at bedtime for 7 days 1, 2
• The American College of Obstetricians and Gynecologists notes that oral metronidazole is contraindicated during the first trimester due to concerns about potential teratogenicity, although meta-analyses do not indicate teratogenicity in humans 2

Second and Third Trimester Treatment Options

• The Centers for Disease Control and Prevention recommends oral metronidazole 250 mg three times daily for 7 days as a treatment option for bacterial vaginosis during the second and third trimesters 3
• Alternative regimens include metronidazole 2g orally in a single dose, clindamycin 300 mg orally twice daily for 7 days, and metronidazole gel 0.75% intravaginally 3

Safety Considerations

• The FDA classifies metronidazole as pregnancy category B, indicating no evidence of harm to the fetus in animal studies, but adequate human studies are lacking, and clindamycin vaginal cream is preferred over oral clindamycin to minimize systemic exposure 1, 2
• Clindamycin vaginal cream should not be confused with clindamycin vaginal ovules, which are not recommended during pregnancy 4

Clinical Implications

• Bacterial vaginosis has been associated with adverse pregnancy outcomes, including premature rupture of membranes, preterm labor, and preterm birth, according to the Centers for Disease Control and Prevention 1, 2, 3
• Treatment of bacterial vaginosis in high-risk pregnant women may reduce the risk of preterm delivery 3, 4

Follow-Up Recommendations

• Follow-up visits are generally unnecessary if symptoms resolve, but for high-risk pregnant women, a follow-up evaluation one month after treatment completion may be considered to ensure successful treatment 3, 5
• Routine treatment of male sex partners is not recommended as it has not been shown to influence treatment response or reduce recurrence rates 3, 6

Treatment of Bacterial Vaginosis in Pregnancy

First Trimester Treatment Considerations

• Clindamycin cream is oil-based and may weaken latex condoms and diaphragms, as noted by the Centers for Disease Control and Prevention 7
• Avoid clindamycin vaginal cream in later pregnancy - evidence from three trials shows increased adverse events (prematurity and neonatal infections) after use of clindamycin cream, particularly in newborns 7

Rationale for Treatment

• Bacterial vaginosis is associated with adverse pregnancy outcomes including premature rupture of membranes, chorioamnionitis, preterm labor, preterm birth, postpartum endometritis, and post-cesarean wound infection 7
• Systemic therapy is preferred over topical therapy to treat possible subclinical upper genital tract infections, but this applies more to women at high risk for preterm delivery 7

Important Clinical Pitfalls

• Do not use metronidazole gel intravaginally during first trimester - existing data do not support the use of topical metronidazole agents during pregnancy 7
• Treatment of male sex partners is not recommended as it does not influence treatment response or reduce recurrence rates 8

Follow-Up Recommendations

• Follow-up visits are unnecessary if symptoms resolve 8

Transition to Second Trimester

• Once the patient enters the second trimester, treatment options expand to include oral metronidazole 250 mg three times daily for 7 days, which becomes the preferred systemic therapy 8

Alternatives to Metronidazole Gel for Bacterial Vaginosis

Primary Alternative: Clindamycin Vaginal Cream

• The CDC recommends clindamycin cream 2% as the preferred alternative to metronidazole gel for bacterial vaginosis, with equivalent efficacy, for patients with metronidazole allergy or intolerance 9, 10
• The standard regimen for clindamycin cream 2% is one full applicator (5 g) intravaginally at bedtime for 7 days, as recommended by the CDC 9, 10
• Clindamycin cream has minimal systemic absorption (approximately 4% bioavailability), reducing systemic side effects, according to the CDC 10

Special Population: Pregnancy First Trimester

• Clindamycin vaginal cream is preferred over oral clindamycin to minimize fetal medication exposure in the first trimester, as recommended by the CDC 9

Special Population: Metronidazole Allergy

• For true metronidazole allergy, clindamycin cream is the only effective alternative, as stated by the CDC 9, 10
• Patients allergic to oral metronidazole should NOT receive metronidazole gel vaginally, according to the CDC 9, 10

Oral Clindamycin Alternative

• The CDC recommends clindamycin 300 mg orally twice daily for 7 days as an alternative to metronidazole gel 10

Metronidazole Safety in Pregnancy

Second and Third Trimester Use

• Meta-analyses have shown no association between metronidazole exposure during later trimesters and preterm birth, low birth weight, or congenital anomalies in pregnant women with bacterial vaginosis, indicating a favorable safety profile for metronidazole in the second and third trimesters 11
• For pregnant women with Crohn's disease requiring antibiotic therapy for perianal sepsis, metronidazole and/or ciprofloxacin are recommended treatment options throughout pregnancy, including the second and third trimesters, according to the American Gastroenterological Association 11
• In a small case series of women with inflammatory bowel disease, neither metronidazole nor ciprofloxacin was associated with poor pregnancy outcomes, such as preterm birth or low birth weight, when used in the second and third trimesters 11

Treatment of Bacterial Vaginosis in Pregnant Women

First-Line Treatment Regimen

• The Centers for Disease Control and Prevention recommends oral clindamycin 300 mg twice daily for 7 days as an alternative regimen if clindamycin vaginal cream is contraindicated, to minimize systemic exposure during the first trimester 12

Rationale for Treatment

• Bacterial vaginosis is associated with serious adverse pregnancy outcomes, and all symptomatic pregnant women should be tested and treated to prevent these complications, according to the Centers for Disease Control and Prevention 12
• The Centers for Disease Control and Prevention suggests that systemic therapy is generally preferred to treat possible subclinical upper genital tract infections, but this principle must be balanced against first-trimester teratogenicity concerns 12

Transition to Second Trimester

• Once the patient enters the second trimester, treatment options expand to include oral metronidazole 250 mg three times daily for 7 days, which becomes the preferred systemic therapy, with no consistent associations between metronidazole use during the second and third trimesters and teratogenic or mutagenic effects in newborns, as reported by the Centers for Disease Control and Prevention 12

Treatment of Amoebiasis in Pregnancy

Alternative Therapies

• The American Gastroenterological Association suggests that metronidazole may be used after the first trimester, with meta-analyses showing no association with preterm birth, low birth weight, or congenital anomalies 13
• The American Gastroenterological Association recommends that metronidazole becomes acceptable after the first trimester, with recent meta-analyses not confirming historical concerns about teratogenicity in humans 13

Management of Bacterial Vaginosis in First‑Trimester Pregnancy

Recommended First‑Trimester Therapy

• The CDC recommends clindamycin vaginal cream 2 % (5 g, one full applicator) administered intravaginally at bedtime for 7 days as the sole first‑trimester treatment for bacterial vaginosis. 14

Treatment Adherence

• Patients should complete the entire 7‑day course even if symptoms resolve before treatment is finished. 14

Contraception Counseling

• Because the cream is oil‑based and weakens latex condoms and diaphragms, patients should use non‑latex barrier methods (or other contraception) during treatment and for several days afterward. 14

Rationale for Treating All Symptomatic Pregnant Women

• All symptomatic pregnant women should be screened and treated for bacterial vaginosis, irrespective of gestational age, since BV is linked to serious adverse pregnancy outcomes such as premature rupture of membranes, chorioamnionitis, preterm labor, preterm birth, postpartum endometritis, and post‑cesarean wound infection. 14
• In women with a prior preterm delivery (high‑risk group), treatment may lower the risk of subsequent preterm birth. 14

Partner Management

• The CDC advises against treating male sexual partners; randomized trials have shown that partner treatment does not improve cure rates, reduce recurrence, or affect therapeutic response. 14

Contraindication in Later Pregnancy

• Clindamycin vaginal cream should not be used in the second or third trimester; three trials reported increased adverse events—including prematurity and neonatal infections—when the cream was used later in pregnancy. 14

Follow‑Up Strategy for High‑Risk Women

• For women with a history of preterm delivery, a follow‑up evaluation approximately one month after completing therapy is recommended to confirm eradication of bacterial vaginosis. 14

Transition to Second‑Trimester Therapy

• Upon entering the second trimester, oral metronidazole 250 mg three times daily for 7 days becomes the preferred systemic option, with no consistent evidence of teratogenic or mutagenic effects in newborns. 14